Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

Freire, Antonio; Melnyk, Vasyl; Kim, Jong Hun; Datsenko, Oleksiy B.; Dzyublik, O. Ya.; Глумчер, Ф. С.; Chuang, Yin Ching; Maroko, Robert; Dukart, Gary; Cooper, C. Angel; Korth‐Bradley, Joan M.; Dartois, Nathalie; Gandjini, Hassan

doi:10.1016/j.diagmicrobio.2010.05.012

Cited by 257 publications

(193 citation statements)

References 34 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Tigecycline was as effective as imipenem-cilastatin in patients who did not require mechanical ventilation, but it was inferior to imipenem-cilastatin for patients receiving mechanical ventilation. 85 In a subset of patients with confirmed MRSA pneumonia, tigecycline was less effective than imipenem-cilastatin plus vancomycin (12/27 vs 23/30 patients, Pϭ.005). 85 One trial comparing linezolid with vancomycin for patients with febrile neutropenia and 11 trials comparing teicoplanin with vancomycin have been published.…”

Section: Vancomycin For Gram-positive Infections: a Meta-analysismentioning

confidence: 98%

“…85 In a subset of patients with confirmed MRSA pneumonia, tigecycline was less effective than imipenem-cilastatin plus vancomycin (12/27 vs 23/30 patients, Pϭ.005). 85 One trial comparing linezolid with vancomycin for patients with febrile neutropenia and 11 trials comparing teicoplanin with vancomycin have been published. In most of these trials antibiotics were administered as first-line empirical treatment.…”

Section: Vancomycin For Gram-positive Infections: a Meta-analysismentioning

confidence: 98%

See 1 more Smart Citation

Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design

Vardakas

Mavros

Roussos

et al. 2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective: To study the effectiveness and safety of vancomycin compared with that of other antibiotics for the treatment of gram-positive infections. Methods: Major electronic databases were searched. Data from published randomized controlled trials (January 1, 1950, to September 15, 2011 were pooled using a meta-analytic method. Results: Fifty-three trials comparing vancomycin with linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, telavancin, teicoplanin, iclaprim, and dalbavancin were included in the meta-analysis. Individual antibiotics were as effective as vancomycin, except for linezolid, which was more effective than vancomycin for the treatment of skin and soft tissue infections (odds ratio [OR], 1.61; 95% confidence interval [CI], 1.07-2.43). Comparators were as effective as vancomycin in the intent-to-treat population (OR, 1.08; 95% CI, 0.98-1.18) but were more effective in the clinically evaluable population (OR, 1.14; 95% CI, 1.02-1.27) when all infections were pooled. When available data from all trials were pooled, no differences were noted when patients with febrile neutropenia (OR, 1.07; 95% CI, 0.82-1.39), pneumonia (OR, 1.10; 95% CI, 0.87-1.37), bacteremia (OR, 1.05; 95% CI, 0.76-1.45), and skin and soft tissue infections (OR, 1.11; 95% CI, 0.89-1.39) were studied. Comparators were more effective in open-label (OR, 1.28; 95% CI, 1.08-1.50) but not in double-blind trials (OR, 1.04; 95% CI, 0.90-1.20). Total adverse events attributed to studied antibiotics (OR, 1.07; 95% CI, 0.90-1.28) and patients withdrawn from trials (OR, 0.86; 95% CI, 0.68-1.09) were similar in the compared groups. Mortality was not different between vancomycin and comparator antibiotics when all trials were included in the analysis (OR, 1.09; 95% CI, 0.96-1.23). Comparators were associated with higher mortality in open-label (OR, 1.27; 95% CI, 1.05-1.54) but not double-blind trials (OR, 0.96; 95% CI, 0.80-1.14). Conclusion: On the basis mainly of data from open-label trials, vancomycin is a treatment choice that is as effective as other available antibiotics for patients with gram-positive infections. Study design seems to make a major contribution to the outcome.

show abstract

Section: Vancomycin For Gram-positive Infections: a Meta-analysismentioning

confidence: 98%

Section: Vancomycin For Gram-positive Infections: a Meta-analysismentioning

confidence: 98%

Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design

Vardakas

Mavros

Roussos

et al. 2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…In the case of tigecycline, there are positive case reports of its use in infections due to K. pneumoniae with VIM and KPC carbapenemases in Greece [15], but also of resistance emerging during therapy, albeit in an off-label setting (nosocomial pneumonia) [16]. Moreover, it is licensed for use only in intra-abdominal and complicated skin and skin-structure infections, and proved inferior to imipenem/cilastatin in ventilator-associated pneumonia, providing a caution against off-label use in this infection [17]. Tigecycline is also probably not appropriate in urinary infections owing to largely biliary excretion and low urinary levels.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Livermore¹,

Warner²,

Mushtaq³

et al. 2011

International Journal of Antimicrobial Agents

304

181

View full text Add to dashboard Cite

“…Alternatives should be considered in patients with severe infections, especially ventilator-associated pneumonia, due to the higher mortality seen in the tigecycline arms of comparative trials, 48,144 Resistance can develop on treatment.…”

Section: Ecil-4 Recommendationsmentioning

confidence: 99%

“…46,48,144 If the underlying problem is the spread of resistant clones of bacterial among the patients in a unit, the best answer is the reinforcement of infection control, not the use of more exotic and complex antimicrobial chemotherapy. Antimicrobial stewardship, aiming to minimize unnecessary broad spectrum antibiotic use and its associated collateral damage and resistance selection is likewise crucial in the present era of growing resistance.…”

mentioning

confidence: 99%

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4 th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o n 2 0 1 3organizing committee and experts were solicited to form the working group. The group reviewed the published English-language literature and prepared proposals on treatment options for infections due to resistant bacteria. Papers for review were sought using PubMed with the terms "linezolid", "daptomycin", "quinupristin/ dalfopristin", "colistin or polymyxin", "tigecycline", "fosfomycin", "telavancin", "ceftaroline" AND "stem cell transplantation or bone marrow transplant or leukemia or hematological malignancy or cancer". References cited in the articles identified were also considered. In respect of 'Duration of therapy', the main search terms used were "antibiotic therapy"; "stem cell transplantation or bone marrow transplantation or hematological malignancy or cancer"; "febrile neutropenia" and "duration therapy", "discontinuation antibiotics" and "microbiologically documented infection". Definitions of resistanceA bacterial isolate was considered non-susceptible if it was categorized resistant, intermediate or non-susceptible when using clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) or the US Food and Drug Administration (FDA). Definitions of 'MDR' vary among authors and usually presume resistance to at least two antibiotics used in empiric therapy (3 rd 4 th -generation cephalosporins, carbapenems or piperacillin/tazobactam) or resistance to at least three of the following antibiotic classes: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. [11][12][13][14][15] According to the recent definition of the European Centre for Disease Prevention and Control...

show abstract

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

Cited by 257 publications

References 34 publications

Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design

Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design

What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Contact Info

Product

Resources

About